Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Future Research Needs For First And Second Generation Antipsychotics For Children And Young Adults
Download Future Research Needs For First And Second Generation Antipsychotics For Children And Young Adults full books in PDF, epub, and Kindle. Read online Future Research Needs For First And Second Generation Antipsychotics For Children And Young Adults ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Future Research Needs for First- and Second-generation Antipsychotics for Children and Young Adults by :
Download or read book Future Research Needs for First- and Second-generation Antipsychotics for Children and Young Adults written by and published by . This book was released on 2012 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: This future research needs (FRN) report is based on an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review (CER) titled "First- and Second-Generation Antipsychotics for Children and Young Adults." The purpose of the CER was to review and synthesize the evidence regarding the benefits and harms of first- and second-generation antipsychotics (FGAs and SGAs) for the treatment of various psychiatric and behavioral conditions in individuals 24 years of age or younger.
Author :U. S. Department of Health and Human Services Publisher :Createspace Independent Pub ISBN 13 :9781484974346 Total Pages :70 pages Book Rating :4.9/5 (743 download)
Book Synopsis Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults by : U. S. Department of Health and Human Services
Download or read book Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-05-14 with total page 70 pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of this future research needs (FRN) report is to develop a list of stakeholders' research needs related to the comparative effectiveness of first- and second-generation antipsychotics (FGAs and SGAs) in pediatric and young adult populations. This FRN report is based on an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review (CER) titled “First- and Second-Generation Antipsychotics for Children and Young Adults.” We reviewed the CER in draft form. The purpose of the CER was to review and synthesize the evidence regarding the benefits and harms of FGAs and SGAs for the treatment of various psychiatric and behavioral conditions in children and young adults 24 years of age or younger. FGAs and SGAs are commonly categorized into two classes. FGAs, also known as typical antipsychotics, were developed in the 1950s. FGAs are used to treat psychotic symptoms such as auditory and visual hallucinations and delusions through several proposed mechanisms, including through the blockade of dopamine neuro-receptors. FGAs are associated with various adverse effects. These side effects include extra-pyramidal symptoms (EPS). EPS is a group of movement disorders, including acute dystonic reactions (severe spasms of various muscle groups), akathisia (a feeling of motor restlessness), pseudo-parkinsonism (medication-induced motor slowness and rigidity), and tardive dyskinesia (repetitive low amplitude movements, most often of facial muscles, insidious and chronic in nature). The most severe antipsychotic-associated potential side effect is neuroleptic malignant syndrome (NMS), characterized by hyperthermia, rigidity, rhabdomyolysis, renal failure, delirium, cardiovascular instability, and death. SGAs, also known as atypical antipsychotics, emerged in the 1980s. SGAs are generally thought to have a lower risk of EPS. The risk of NMS is rare for both medication classes, and researchers are uncertain about whether there is an intra-class risk difference for NMS. However, SGAs are associated with a higher risk of a range of metabolic side effects, including weight gain; dyslipidemia; insulin resistance; the development of type 2 diabetes; and, rarely, hyperglycemic coma. The review1 was prompted by the observation that the use of antipsychotics, particularly SGAs, for children and adolescents has increased markedly during the past 20 years. Prescribing antipsychotics to the pediatric population is controversial because of a relative lack of high-quality and longitudinal studies on which to base clinical practice recommendations. For the majority of antipsychotic drugs, approved indications in the United States are restricted to the treatment of childhood schizophrenia and bipolar disorders. The U.S. Food and Drug Administration (FDA) approved risperidone in 2006 and aripiprazole in 2009 for the treatment of irritability associated with autism. Off-label prescriptions are given to younger children for a range of indications including behavioral symptoms (e.g., aggression) that are related to diagnosable conditions (e.g., attention deficit hyperactivity disorder [ADHD]). In general, much prescribing of SGAs for children and adolescents does not appear to be guided by evidence of clinical benefit or risk of harms.
Book Synopsis First- and Second-Generation Antipsychotics for Children and Young Adults by :
Download or read book First- and Second-Generation Antipsychotics for Children and Young Adults written by and published by . This book was released on 2012 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update by :
Download or read book First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update written by and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author :U. S. Department of Health and Human Services Publisher :Createspace Independent Pub ISBN 13 :9781484133873 Total Pages :402 pages Book Rating :4.1/5 (338 download)
Book Synopsis First- and Second-Generation Antipsychotics for Children and Young Adults by : U. S. Department of Health and Human Services
Download or read book First- and Second-Generation Antipsychotics for Children and Young Adults written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-04-16 with total page 402 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antipsychotic medications are widely used to treat several psychiatric disorders and are commonly categorized into two classes. First-generation antipsychotics (FGAs), also known as typical antipsychotics, were developed in the 1950s. Although they are used to treat psychotic symptoms, they are associated with various side effects including extrapyramidal symptoms, which are movement disorders characterized by repetitive, involuntary muscle movements, restlessness, or an inability to initiate movement. Other common side effects are dry mouth and sedation. Neuroleptic malignant syndrome and tardive dyskinesia are rare but serious side effects. Second-generation antipsychotics (SGAs), also known as atypical antipsychotics, emerged in the 1980s. They are generally thought to have a lower risk of motor side effects. However, SGAs are associated with a higher risk of weight gain, elevated lipid and prolactin levels, and development of type 2 diabetes. Use of antipsychotics for children and adolescents has increased during the past 20 years. Prescribing antipsychotics to the pediatric population is controversial because there are few high quality and longitudinal studies on which to base clinical practice recommendations. For the majority of antipsychotic drugs, approved indications in the U.S. are restricted to the treatment of childhood schizophrenia and bipolar disorders. In 2006, the U.S. Food and Drug Administration (FDA) approved risperidone and aripiprazole for the treatment of irritability associated with autism. Off-label prescriptions are given to younger children for behavioral symptoms that are related to diagnosable conditions. In general, the choice of medication in children and adolescents is often driven by side-effect profiles that may affect growth and development, medication adherence and persistence, as well as other important domains such as school performance and health-related quality of life. This review provides a comprehensive synthesis of the evidence examining the benefits and harms associated with the use of FDA-approved FGAs and SGAs in children, adolescents, and young adults less than or equal to 24 years of age. The Key Questions are as follows: 1. What is the comparative efficacy or effectiveness of FGAs and SGAs for treating disorder- or illness-specific and nonspecific symptoms in children, youth, and young adults for the following disorders or illnesses? Pervasive developmental disorders, including autistic disorder, Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified; ADHD and disruptive behavior disorders, including conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified; Pediatric bipolar disorder, including manic or depressive phases, rapid cycling, and mixed states; Schizophrenia and schizophrenia-related psychoses, including schizoaffective disorder and drug-induced psychosis; Obsessive-compulsive disorder; Post-traumatic stress disorder; Anorexia nervosa; Tourette syndrome; Behavioral issues, including aggression, agitation, anxiety, behavioral dyscontrol, irritability, mood lability, self-injurious behaviors, and sleep disorders. 2. Do FGAs and SGAs differ in medication-associated adverse events when used in children, youth, and young adults? 3. Do FGAs and SGAs differ in other short- and long-term outcomes when used in children, youth, and young adults? 4. Do the effectiveness and risks of FGAs and SGAs vary in differing subpopulations including: Sex? Age group (less than 6 years [preschool], 6–12 years [preadolescent], 13–18 years [adolescent], 19–24 years [young adult])? Race? Comorbidities, including substance abuse and ADHD? Cotreatment versus monotherapy? First-episode psychosis versus treatment in context of history of prior episodes (related to schizophrenia)? Duration of illness? Treatment naïve versus history of previous antipsychotics use?
Book Synopsis First- and Second-generation Antipsychotics in Children and Young Adults by : Jennifer Pillay
Download or read book First- and Second-generation Antipsychotics in Children and Young Adults written by Jennifer Pillay and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: OBJECTIVES: To review the evidence on first- and second-generation antipsychotics (FGAs and SGAs) for the treatment of various psychiatric and behavioral conditions in children, adolescents, and young adults (ages d 24 years). DATA SOURCES: Eight electronic databases, gray literature, trial registries, and reference lists. METHODS: Two reviewers conducted study selection and risk of bias assessment independently, and resolved discrepancies by consensus. One reviewer extracted and a second verified the data. We conducted meta-analyses when appropriate and network meta-analysis across conditions for changes to body composition. We rated strength of evidence for prespecified outcomes. RESULTS: One hundred thirty-five studies (95 trials and 40 observational studies) were included. None of the evidence was rated as high strength of evidence; results having moderate strength (i.e., probably an accurate effect) are presented (with n studies) below.SCHIZOPHRENIA AND RELATED PSYCHOSES (N = 39): Compared with placebo, SGAs as a class probably increase response rates, decrease slightly (not clinically significant for many patients) negative and positive symptoms, and improve slightly global impressions of improvement, severity, and functioning. There is likely little or no difference between high and low doses of quetiapine for clinical severity and functioning. Many outcomes for individual drug comparisons were of low or insufficient strength of evidence. BIPOLAR DISORDER (N = 19): Compared with placebo, SGAs probably decrease mania, decrease depression symptoms slightly, and improve symptom severity and global functioning to a small extent. SGAs (and aripiprazole alone) probably increase response and remission rates versus placebo for manic/mixed phases. Quetiapine likely makes little or no difference in depression. AUTISM SPECTRUM DISORDERS (N = 23): Compared with placebo, SGAs as a class probably decrease irritability, and decrease slightly lethargy/social withdrawal, stereotypy, and inappropriate speech; they likely increase response rates and (slightly) clinical severity. It is likely that aripiprazole and risperidone decrease irritability. ATTENTION DEFICIT HYPERACVTIVITY DISORDER (ADHD) AND DISRUPTIVE, IMPULSE-CONTROL, AND CONDUCT DISORDERS (N = 13): Compared with placebo, SGAs as a class (and risperidone individually) probably decrease conduct problems and aggression. Risperidone alone likely decreases hyperactivity in children with a primary diagnosis of conduct disorders or with ADHD but not responding to stimulants. OTHER CONDITIONS: All outcomes had low or insufficient strength of evidence for tic disorders (n = 12), obsessive-compulsive disorder (n = 1), depression (n = 1), eating disorders (n = 3), and behavioral issues (n = 2). HARMS ACROSS CONDITIONS: From network meta-analysis, olanzapine was more harmful for gains in weight and body mass index (BMI) than other SGAs except for clozapine and lurasidone; results were most robust for relative harm over aripiprazole, quetiapine, and risperidone, and most applicable to the short term. Findings from pairwise meta-analysis between different SGAs were similar, except for showing longer term benefit for quetiapine and risperidone versus olanzapine, and little or no short-term differences between risperidone and quetiapine, or between different doses of aripiprazole, asenapine, or quetiapine. FGAs probably cause slightly less harm for weight and BMI compared with SGAs. There is probably little or no difference in risk for somnolence between different doses of asenapine or quetiapine. There is likely little or no difference in risk for mortality or prolonged QT interval in the short term for SGAs as a class. SGAs versus placebo/no treatment probably increase short-term risk for high triglyceride levels, extrapyramidal symptoms, sedation, and somnolence. CONCLUSION: SGAs probably improve to some extent key intermediate outcomes for which they are usually prescribed, but they have a poorer harms profile than placebo or no antipsychotic treatment, particularly for body composition and somnolence. Data for head-to-head comparisons within and between classes were generally limited and rated as insufficient or low strength of evidence. Evidence was sparse for patient-important outcomes (e.g., health-related quality of life) and outcomes for young children (
Author :National Collaborating Centre for Mental Health (Great Britain) Publisher :RCPsych Publications ISBN 13 :9781908020604 Total Pages :512 pages Book Rating :4.0/5 (26 download)
Book Synopsis Psychosis and Schizophrenia in Children and Young People by : National Collaborating Centre for Mental Health (Great Britain)
Download or read book Psychosis and Schizophrenia in Children and Young People written by National Collaborating Centre for Mental Health (Great Britain) and published by RCPsych Publications. This book was released on 2013 with total page 512 pages. Available in PDF, EPUB and Kindle. Book excerpt: These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.
Author :Virginia Poole Arcangelo Publisher :Lippincott Williams & Wilkins ISBN 13 :1496351843 Total Pages :2341 pages Book Rating :4.4/5 (963 download)
Book Synopsis Pharmacotherapeutics for Advanced Practice by : Virginia Poole Arcangelo
Download or read book Pharmacotherapeutics for Advanced Practice written by Virginia Poole Arcangelo and published by Lippincott Williams & Wilkins. This book was released on 2016-06-09 with total page 2341 pages. Available in PDF, EPUB and Kindle. Book excerpt: Be ready to prescribe and administer drugs safely and effectively—and grasp all the vitals of pharmacology—with the fully updated Pharmacotherapeutics for Advanced Practice, 4th edition. Written by pharmacology nursing experts, this easy-to-read text offers proven frameworks for treating more than 50 common diseases and disorders. Learn how to identify disorders, review possible therapies, then prescribe and monitor drug treatment, accurately. Based on current evidence and real-life patient scenarios, this is the perfect pharmacology learning guide and on-the-spot clinical resource. Absorb the key principles and practical methods for accurate prescribing and monitoring, with . . . NEW chapter on Parkinson’s disease, osteoarthritis, and rheumatoid arthritis NEW and updated therapies, and updated and additional case studies, with sample questions NEW content on the impacts of the Affordable Care Act Updated chapters on complementary and alternative medicine (CAM) and pharmacogenomics Updated evidence-based algorithms and drug tables – Listing uses, mechanisms, adverse effects, drug interactions, contraindications, and monitoring parameters, organized by drug class; quick access to generic and trade names and dosages Quick-scan format organizes information by body system Chapter features include: Brief overview – Pathophysiology of each disorder, and relevant classes of drugs Monitoring Patient Response section – What to monitor, and when Patient Education section – Includes information on CAM for each disorder Drug Overview tables – Usual dose, contraindications and side effects, and special considerations Algorithms – Visual cues on how to approach treatment Updated Recommended Order of Treatment tables – First-, second- and third-line drug therapies for each disorder Answers to Case Study Questions for each disorder – Strengthens critical thinking skills Selecting the Most Appropriate Agent section – The thought process for choosing an initial drug therapy Principles of Therapeutics unit – Avoiding medication errors; pharmacokinetics and pharmacodynamics; impact of drug interactions and adverse events; principles of pharmacotherapy for pediatrics, pregnancy/lactation, and geriatrics Disorders units – Pharmacotherapy for disorders in various body systems Pharmacotherapy in Health Promotion unit – Smoking cessation, immunizations, weight management Women’s Health unit – Including contraception, menopause, and osteoporosis Integrative Approach to Patient Care unit – Issues to consider when presented with more than one diagnosis Standard pharmacotherapeutics text for nurse practitioners, students, and physician assistants Ancillaries – Case Study answers, multiple choice questions and answers for every chapter, PowerPoints, Acronyms List
Book Synopsis Pediatric Drug Development by : Andrew E. Mulberg
Download or read book Pediatric Drug Development written by Andrew E. Mulberg and published by John Wiley & Sons. This book was released on 2013-05-20 with total page 782 pages. Available in PDF, EPUB and Kindle. Book excerpt: Most medicines have never been adequately tested for safety and efficacy in pediatric populations and preterm, infants and children are particularly vulnerable to adverse drug reactions. Pediatric Drug Development: Concepts and Applications, Second Edition, addresses the unique challenges in conducting effective drug research and development in pediatric populations. This new edition covers the legal and ethical issues of consent and assent, the additional legal and safety protections for children, and the appropriate methods of surveillance and assessment for children of varying ages and maturity, particularly for patient reported outcomes. It includes new developments in biomarkers and surrogate endpoints, developmental pharmacology and other novel aspects of global pediatric drug development. It also encompasses the new regulatory initiatives across EU, US and ROW designed to encourage improved access to safe and effective medicines for children globally. From an international team of expert contributors Pediatric Drug Development: Concepts and Applications is the practical guide to all aspects of the research and development of safe and effective medicines for children.
Book Synopsis Top Topics in Child & Adolescent Psychiatry, An Issue of Child and Adolescent Psychiatric Clinics of North America by : Harsh K. Trivedi
Download or read book Top Topics in Child & Adolescent Psychiatry, An Issue of Child and Adolescent Psychiatric Clinics of North America written by Harsh K. Trivedi and published by Elsevier Health Sciences. This book was released on 2014-12-27 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this issue of Child & Adolescent Psychiatric Clinics, consulting editor Dr. Harsh Trivedi has selected topics that continually are at the forefront for child and adolescent psychiatrists.Among the top topics are: Children's Exposure to Violent Video Games and Desensitization to Violence; Neurobiology of Attention Deficit Hyperactivity Disorder; Psychosocial Interventions in Attention Deficit Hyperactivity Disorder; 5. Social Skills Training for Youth with Autism Spectrum Disorders; 6. Complementary and Alternative Medicine Treatments for Children with Autism Spectrum Disorders; and Adolescent Eating Disorders: Definitions, Symptomatology, Epidemiology and Comorbidity. Authors renown in the psychiatric field and the pediatric field provide the physician clinical outcomes and therapeutic management of these disorders.
Book Synopsis Tasman’s Psychiatry by : Allan Tasman
Download or read book Tasman’s Psychiatry written by Allan Tasman and published by Springer Nature. This book was released on 2024-09-30 with total page 5496 pages. Available in PDF, EPUB and Kindle. Book excerpt: Authored by over 500 internationally acclaimed expert editors and chapter authors from around the world. Completely updated and expanded with almost 40 new chapters. Significantly increased attention to the role of culture in all aspects of evaluation and care. New sections on Digital Mental Health Services and Technologies, Treatment Issues in Specific Populations and Settings, and on Prevention, Systems of Care, and Psychosocial Aspects of Treatment address key advances. This edition is the first comprehensive reference work to cover the entire field of psychiatry in an updateable format, ensuring access to state of the art information. Earlier editions were called “the best current textbook of psychiatry” by the New England Journal of Medicine, and “the gold standard” by the American Journal of Psychiatry. Tasman’s Psychiatry, 5th Edition, builds on the initial vision in prior editions of approaching psychiatric evaluation and care from an integrative bio-psycho-social-cultural perspective. It is designed to be an essential and accessible reference for readers at any level of experience. This editorial approach encompasses the importance of the first encounter between patient and clinician, followed by the complex task of beginning to develop a therapeutic relationship and to develop and implement a treatment plan in collaboration with the patient. The importance of increasing attention to the role of culture and social determinants of mental health is reflected both in specific chapters and in components of many chapters throughout the book, especially in those pertaining to clinical evaluation, the therapeutic alliance, and treatment. The global scope of this edition is reflected throughout the book, including the section on psychiatric disorders where evaluation using both ICD 11 and DSM 5-TR is discussed. Most chapters are authored by experts from at least two different countries or continents, adding a critically important dimension which often is missing in major psychiatric textbooks. Tasman’s Psychiatry, 5th Edition, is an essential reference for all medical professionals and students who need a trusted reference or learning tool for psychiatry, psychology, clinical research, social work, counseling, therapy, and all others.
Book Synopsis Psychiatric Diagnosis and Management in Primary Care, An Issue of Medical Clinics, E-Book by : Genevieve Pagalilauan
Download or read book Psychiatric Diagnosis and Management in Primary Care, An Issue of Medical Clinics, E-Book written by Genevieve Pagalilauan and published by Elsevier Health Sciences. This book was released on 2014-09-28 with total page 321 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue of the Medical Clinics of North America is devoted to Psychiatric Diagnosis and Management in Primary Care and is edited by Dr. Genevieve Pagalilauan. Articles in this issue include: Psychopharmacology; Office-based Screening of Common Psychiatric Conditions; Depression; Anxiety Disorders; Bipolar Disorder; Borderline Personality Disorder; Grief Reaction, Adjustment Disorder, Seasonal Affective Disorder; Somatiform Disorders; Addiction Disorders; Sleep disorders; Geriatric Psychiatry; Autism Spectrum Disorders in Adults; and Medical Conditions with Neuropsychiatric Manifestations.
Book Synopsis Pediatric Emergencies, An Issue of Pediatric Clinics by : Richard Lichtenstein
Download or read book Pediatric Emergencies, An Issue of Pediatric Clinics written by Richard Lichtenstein and published by Elsevier Health Sciences. This book was released on 2013-10-15 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt: The care of children with acute medical problems is evolving as knowledge of new conditions develops. In addition, technology also changes to provide solutions to optimize care. This issue of PCNA highlights the important populations, disease states, and technological advancements in pediatric emergency medicine. Although concussion and head injury are common occurrences for the practicing pediatrician, we now better understand how to evaluate and manage these children and to use CT scans appropriately. Pediatric offices need to be incorporated in any emergency plan for both acute emergencies and common injuries. Analgesia and sedation must always be considered to provide comfort for children. Technologically assisted children and children with acute psychiatric and behavioral problems are now more commonplace in the Emergency Department as well as the office setting, and the practicing pediatrician needs to have a clear plan in understanding these medical conditions and appropriate management and referral. New drugs of abuse and foreign body ingestions are prevalent and have unique diagnostic and treatment challenges. Skin infections and abscesses have always been common but our knowledge of resistance patterns and best practices for treatment is changing. Finally, whether it is the pediatric office practitioner or the Emergency medicine physician, we need to continue our important efforts in injury prevention for the future of our children.
Book Synopsis Neurodevelopmental Pediatrics by : David D. Eisenstat
Download or read book Neurodevelopmental Pediatrics written by David D. Eisenstat and published by Springer Nature. This book was released on 2023-02-22 with total page 816 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explores the interrelationship of genetics, the environment, or both, in the causation of three neurodevelopmental disorders: autism/autism spectrum disorder (ASD), fetal alcohol spectrum disorder (FASD), and cerebral palsy (CP). It links common clinical problems in developmental pediatrics and pediatric neurology to current concepts and translational research advances in developmental neurosciences, medical genetics, and related disciplines. The first section of the book provides a comprehensive and up-to-date overview of development of the brain, including topics such as neuronal stem cells, epigenetics, and the influence of the prenatal environment. The next three sections analyze the epidemiology, diagnosis, interventions, and controversies and research directions associated with each of the three neurodevelopmental disorders. It also examines co-morbidities common to all three disorders, such as disturbed sleep, seizures, behavioral disorders, and pain. It concludes by highlighting the impact of ASD, FASD, and CP on family dynamics and provides tools and resources based on foundational concepts such as neuroethics, bioinformatics, community engagement, and advocacy. Learning objectives, key points, clinical vignettes, and multiple choice questions are incorporated throughout the book. With its comprehensive treatment of disease mechanisms, genetics, and pathophysiology associated with these disorders and its discussion of potential therapies and novel treatments, Neurodevelopmental Pediatrics: Genetic and Environmental Influences is an essential resource for developmental pediatricians, child neurologists, fellows, residents and graduate students.
Book Synopsis Schizophrenia Treatment Outcomes by : Amresh Shrivastava
Download or read book Schizophrenia Treatment Outcomes written by Amresh Shrivastava and published by Springer Nature. This book was released on 2020-02-05 with total page 351 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book analyzes schizophrenia management in the context of recent clinical therapeutic advances that have transformed the measurements and outcomes landscape. Unlike any other resource, this volume carefully develops the social and clinical guidelines that affect the life of the patient and defines its role in schizophrenia treatment outcomes. The text begins by determining the concepts, development, neuroscience, and guidelines for positive outcomes before analyzing the gaps in the literature. The text addresses medical concerns in relation to outcomes in schizophrenic patients, including substance use, impact from antipsychotic medications, and medical comorbidities. The text also covers external determinants that may inhibit positive outcomes, including cultural factors, stigma, and environmental issues. Written by experts in schizophrenia care, this book compiles sound research, current clinical trends, and modern measurement markers into a well-organized compendium that delivers this data into a practical guide for measuring treatment outcomes in patients suffering from the disease. Schizophrenia Treatment Outcomes is the ultimate guide for psychiatrists, psychologists, nurses, social workers, and all medical practitioners interested in improving outcomes for schizophrenia patients.
Book Synopsis Treatment–Refractory Schizophrenia by : Peter F. Buckley
Download or read book Treatment–Refractory Schizophrenia written by Peter F. Buckley and published by Springer Science & Business Media. This book was released on 2014-03-18 with total page 231 pages. Available in PDF, EPUB and Kindle. Book excerpt: Schizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.
Book Synopsis Psychiatric Nonadherence by : Victor Fornari
Download or read book Psychiatric Nonadherence written by Victor Fornari and published by Springer. This book was released on 2019-04-04 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explores medical nonadherence to treatment and management of psychiatric disorders across the lifespan. Leading experts in the field, specializing in a range of mental health problems describe the impact of nonadherence in the treatment of children, adolescents, transition age youths, adults, and older adults. The book eloquently articulates the key elements of effective physicians and offers clinical pearls on professionalism, empathy, and the doctor-patient relationship—a key component to solving treatment nonadherence. This volume focuses on solutions for improved clinical outcomes, including communication skills, empathy and building trust, motivational interviewing techniques and the use of technology. Psychiatric Nonadherence is an excellent resource for all clinicians who care for individuals with psychiatric illness. This timely reference will provide guidance to enhance effective treatment adherence for a wide array of medical practitioners, including child and adolescent, adult forensic, and geriatric psychiatrists, addiction medicine specialists, primary care physicians, psychologists and nurses.
